Neurimmune AG
Quick facts
Phase 3 pipeline
- ALXN2220 · Neurology
ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: